Return to Listing

11 result(s) for

PI Name Protocol # Title
Adel Kardosh STUDY00015495 A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)
Skye Mayo STUDY00016033 A Phase II study of induction systemic mFOLFIRINOX followed by hepatic arterial infusion of Floxuridine and Dexamethasone given concurrently with systemic mFOLFIRI as a first-line therapy in patients with unresectable liver-dominant intrahepatic cholangiocarcinoma
Charles Lopez STUDY00017094 A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Adel Kardosh STUDY00018340 A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Skye Mayo STUDY00018937 A Phase II Trial of Perioperative CV301 Vaccination in Combination with Nivolumab and Systemic Chemotherapy for Resectable Hepatic-Limited Metastatic Colorectal Cancer
Adel Kardosh STUDY00019296 A randomized, multicenter, parallel-group, Phase III study to compare the efficacy of arfolitixorin versus leucovorin in combination with 5-fluorouracil, oxaliplatin, and bevacizumab in patients with advanced colorectal cancer
Charles Lopez STUDY00019576 Phase 1b Study to Assess the Safety of Neoadjuvant TAS-102 (triFluridine/tIpiracil) with ConcurrEnt Radiation in Previously Untreated Resectable Stage II and Stage III ReCtal CancEr (FIERCE)
Adel Kardosh STUDY00020980 Phase II randomized multi-center trial of total neoadjuvant therapy with and without CD40 agonist, APX005M, for locally advanced rectal adenocarcinoma
Charles Lopez STUDY00021614 NeoOPTIMIZE: an open-label, phase II trial to assess the efficacy of adaptive switching of modified FOLFIRINOX or Gemcitabine/nab-Paclitaxel as a neoadjuvant strategy for patients with resectable and borderline resectable pancreatic cancer.
Emerson Chen STUDY00021790 An open-label, randomised, multicentre, phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracil/leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas
Emerson Chen STUDY00022189 PRESERVE 1: A Phase 3 Randomized, Double-blind Trial of Trilaciclib versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
 

You may also qualify for Phase 1 Program trials.

 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080